Innovent’s Adalimumab And Bevacizumab Get New Indications In China
New Indications Include Treatment of Psoriasis, Uveitis And Glioblastoma
Executive Summary
Chinese biotech specialist Innovent Biologics has received approval for new indications for its adalimumab and bevacizumab biosimilars from China’s NMPA.
You may also be interested in...
Innovent Expands Internationally With Indonesia Deal
Innovent Biologics has broadened its international reach by striking a licensing deal with PT Etana Biotechnologies in Indonesia for its Byvasda bevacizumab biosimilar.
Lilly And Innovent’s Rituximab Gets Chinese Nod
Eli Lilly and Chinese biotech specialist Innovent Biologics have received approval in China for their biosimilar rituximab, Halpryza. The companies are continuing to co-develop and commercialize other oncology medicines for the Chinese market.
Coherus Acquires Bevacizumab Rights From Innovent
Coherus BioSciences has struck a deal with China’s Innovent Biologics that gives it US and Canadian rights to a bevacizumab biosimilar version of Avastin as well as an option to market Innovent’s rituximab rival to Rituxan in the US and Canada.